The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
Open accessAbstract
Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells. We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization. Chk1 phosphorylation was used to indicate ATR activity, γH2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity. Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo. Murine intestinal damage was evaluated after abdominal XRT. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Guidelines for the welfare and use of animals in cancer research
An ad hoc committee of the National Cancer Research Institute, Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,442
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 4×
“(Rahway, NJ, USA)(45) Tumor cells, normal human fibroblast cells (MRC5: CCL-171; and HFL-1: CCL-153) and the primary PDAC line (PancM; passage 17) were obtained and cultured as previously described.(15,31,46) HDMECs (Lonza, Slough, UK) were cultured as reported.”
BackgroundMethodInfluentialHuguet, F., André, T., Hammel, P., Artru, P., Balosso, J., Selle, F., Deniaud-Alexandre, E., Ruszniewski, P., Touboul, E., Labianca, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5663 · Cited by 529
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
Murga, M., Bunting, S., Montaña, M. F., Soria, R., Mulero, F., Cañamero, M., Lee, Y., McKinnon, P. J., Nussenzweig, A., & Fernandez-Capetillo, O. (2009) · Nature Genetics · doi:10.1038/ng.420 · Cited by 340
Vispe, S., Cazaux, C., Lesca, C., & Defais, M. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.12.2859 · Cited by 318
Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3
Sidi, S., Sanda, T., Kennedy, R. D., Hagen, A. T., Jette, C. A., Hoffmans, R., Pascual, J., Imamura, S., Kishi, S., Amatruda, J. F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.037 · Cited by 297
Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
Charrier, J.-D., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 255
Self-citationPrevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
Self-citationGilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 228
Potten, C. S., Merritt, A., Hickman, J., Hall, P., & Faranda, A. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550101 · Cited by 201
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Chk1 and p21 Cooperate to Prevent Apoptosis during DNA Replication Fork Stress
Rodriguez, R., & Meuth, M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0594 · Cited by 182
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., Fernandez-Capetillo, O., Diehl, J. A., & Brown, E. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58928 · Cited by 182
Morphologic response of the mucosa of human small intestine to x-ray exposure.
Trier, J. S., & Browning, T. H. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105332 · Cited by 179
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 170
Self-citationATR and Chk1 Suppress a Caspase-3–Dependent Apoptotic Response Following DNA Replication Stress
Myers, K. N., Gagou, M. E., Zuazua‐Villar, P., Rodríguez, R., & Meuth, M. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000324 · Cited by 148
Fokas, E., Im, J. H., Hill, S. A., Yameen, S., Stratford, M. R. L., Beech, J. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2263 · Cited by 131
Self-citationPrevo, R., Deutsch, É., Sampson, O. L., Diplexcito, J., Cengel, K. A., Harper, J. V., O’Neill, P., McKenna, W. G., Patel, S. K., & Bernhard, E. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0757 · Cited by 118
Self-citationAnsari, D., Rosendahl, A. H., Elebro, J., & Andersson, R. E. (2011) · British journal of surgery · doi:10.1002/bjs.7574 · Cited by 107
Okazaki, T., Javle, M. M., Tanaka, M., Abbruzzese, J. L., & Li, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1555 · Cited by 104
ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint
Nghiem, P., Park, P. K., Kim, Y.-S., Desai, B. N., & Schreiber, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106113200 · Cited by 99
Ruzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009) · Nature Genetics · doi:10.1038/ng.441 · Cited by 97
Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Lim, K., Chung, E., Khan, A. S., Cao, D., Linehan, D. C., Ben‐Josef, E., & Wang‐Gillam, A. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0268 · Cited by 87
The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation
Hammond, E. M., & Giaccia, A. J. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.035 · Cited by 85
Self-citationMartin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0248 · Cited by 83
Self-citationFokas, E., Yoshimura, M., Prevo, R., Higgins, G. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W., & Muschel, R. J. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-48 · Cited by 80
Self-citationPancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras
Brunner, T. B., Cengel, K. A., Hahn, S. M., Wu, J., Fraker, D. L., McKenna, W. G., & Bernhard, E. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0158 · Cited by 79
Self-citationTao, Y., Leteur, C., Yang, C., Ping, Z., Castedo, M., Pierré, A., Golsteyn, R. M., Bourhis, J., Kroemer, G., & Deutsch, É. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8203 · Cited by 71
Imaging DNA Damage In Vivo Using γH2AX-Targeted Immunoconjugates
Cornelissen, B. T., Kersemans, V., Darbar, S., Thompson, J. M., SHAH, K. A., Sleeth, K. M., Hill, M. A., & Vallis, K. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4587 · Cited by 69
Self-citationATR mediates cisplatin resistance in a p53 genotype-specific manner
Sangster‐Guity, N., Conrad, B., Papadopoulos, N., & Bunz, F. (2011) · Oncogene · doi:10.1038/onc.2010.624 · Cited by 65
Frankenberg-Schwager, M., Gebauer, A., Koppe, C., Wolf, H., Pralle, E., & Frankenberg, D. (2009) · Radiation Research · doi:10.1667/rr0784.1 · Cited by 64
Wilsker, D. F., & Bunz, F. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0679 · Cited by 57
The role of radiotherapy in multimodal treatment of pancreatic carcinoma
Brunner, T. B., & Scott-Brown, M. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-64 · Cited by 49
Self-citationThe importance of local control in pancreatic cancer
Ben‐Josef, E., & Lawrence, T. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.182 · Cited by 21
Cited by
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
Flynn, R. L., Cox, K. E., Jeitany, M., Wakimoto, H., Bryll, A. R., Ganem, N. J., Bersani, F., Pineda, J. R., Suvà, M. L., Benes, C. H., et al. (2015) · Science · doi:10.1126/science.1257216 · Cited by 506
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Metadata
- Authors
- Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W., Muschel, R. J., & Brunner, T. B.
- Venue
- Cell Death & Disease
- Published
- 2012-12-06
- Volume
- 3
- Issue
- 12
- Pages
- e441-e441
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2013895149
- Cited by
- 369
- References
- 47
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.